Anti-TNFRSF4 therapeutic antibody (Pre-made Ivuxolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ivuxolimab (also known as PF 4518600 or PF 8600) is an OX40 receptor agonist, as an intravenous therapy for solid tumours is in development with Pfizer.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-285-1mg	1mg	3090
GMP-Bios-ab-285-10mg	10mg	21890
GMP-Bios-ab-285-100mg	100mg	148000
GMP-Bios-ab-285-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-TNFRSF4 therapeutic antibody (Pre-made Ivuxolimab biosimilar,Whole mAb)
INN Name	Ivuxolimab
Target	TNFRSF4
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California
Conditions Approved	na
Conditions Active	Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma
Conditions Discontinued	na
Development Tech	na